These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31023744)

  • 1. Hairpin and allosteric regulation in ADAMTS13.
    Chung DW
    Blood; 2019 Apr; 133(17):1800-1801. PubMed ID: 31023744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the "minimal" structure of a functional ADAMTS13 by mutagenesis and small-angle X-ray scattering.
    Zhu J; Muia J; Gupta G; Westfield LA; Vanhoorelbeke K; Tolia NH; Sadler JE
    Blood; 2019 Apr; 133(17):1909-1918. PubMed ID: 30692120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phylogenetic and functional analysis of ADAMTS13 identifies highly conserved domains essential for allosteric regulation.
    Muia J; Zhu J; Greco SC; Vanhoorelbeke K; Gupta G; Westfield LA; Sadler JE
    Blood; 2019 Apr; 133(17):1899-1908. PubMed ID: 30700419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric activation of ADAMTS13 by von Willebrand factor.
    Muia J; Zhu J; Gupta G; Haberichter SL; Friedman KD; Feys HB; Deforche L; Vanhoorelbeke K; Westfield LA; Roth R; Tolia NH; Heuser JE; Sadler JE
    Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18584-9. PubMed ID: 25512528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structure and substrate-induced activation of ADAMTS13.
    Petri A; Kim HJ; Xu Y; de Groot R; Li C; Vandenbulcke A; Vanhoorelbeke K; Emsley J; Crawley JTB
    Nat Commun; 2019 Aug; 10(1):3781. PubMed ID: 31439947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro characterization of a novel Arg102 mutation in the ADAMTS13 metalloprotease domain.
    De Waele L; Vermeersch L; Nguyen TT; Tersteeg C; De Meyer SF; Voet A; Pavenski K; Vanhoorelbeke K
    J Thromb Haemost; 2023 Mar; 21(3):682-690. PubMed ID: 36696198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura.
    Halkidis K; Zheng XL
    J Thromb Haemost; 2022 Oct; 20(10):2197-2203. PubMed ID: 35842925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model for the conformational activation of the structurally quiescent metalloprotease ADAMTS13 by von Willebrand factor.
    South K; Freitas MO; Lane DA
    J Biol Chem; 2017 Apr; 292(14):5760-5769. PubMed ID: 28209710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice.
    Liu-Chen S; Connolly B; Cheng L; Subramanian RR; Han Z
    Sci Rep; 2018 May; 8(1):7859. PubMed ID: 29777164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into ADAMTS13 structure: impact on thrombotic thrombocytopenic purpura diagnosis and management.
    Roose E; Veyradier A; Vanhoorelbeke K
    Curr Opin Hematol; 2020 Sep; 27(5):320-326. PubMed ID: 32740038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADAMTS13: more than a regulator of thrombosis.
    Feng Y; Li X; Xiao J; Li W; Liu J; Zeng X; Chen X; Chen S
    Int J Hematol; 2016 Nov; 104(5):534-539. PubMed ID: 27696191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the ADAMTS13 cysteine-rich domain in VWF binding and proteolysis.
    de Groot R; Lane DA; Crawley JT
    Blood; 2015 Mar; 125(12):1968-75. PubMed ID: 25564400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in the x-ray solution scattering of aspartate transcarbamylase following the allosteric transition.
    Moody MF; Vachette P; Foote AM
    J Mol Biol; 1979 Oct; 133(4):517-32. PubMed ID: 395314
    [No Abstract]   [Full Text] [Related]  

  • 14. A functional calcium-binding site in the metalloprotease domain of ADAMTS13.
    Gardner MD; Chion CK; de Groot R; Shah A; Crawley JT; Lane DA
    Blood; 2009 Jan; 113(5):1149-57. PubMed ID: 19047683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VWF and ADAMTS13 behavior in estradiol-treated HUVEC.
    Powazniak Y; Kempfer AC; Pereyra JC; Palomino JP; Lazzari MA
    Eur J Haematol; 2011 Feb; 86(2):140-7. PubMed ID: 20958794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic studies on ADAMTS13 catalysis.
    Di Stasio E; Lancellotti S; Peyvandi F; Palla R; Mannucci PM; De Cristofaro R
    Biophys J; 2008 Sep; 95(5):2450-61. PubMed ID: 18502798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor.
    Pruss CM; Notley CR; Hegadorn CA; O'Brien LA; Lillicrap D
    Br J Haematol; 2008 Nov; 143(4):552-8. PubMed ID: 18986390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential role of the disintegrin-like domain in ADAMTS13 function.
    de Groot R; Bardhan A; Ramroop N; Lane DA; Crawley JT
    Blood; 2009 May; 113(22):5609-16. PubMed ID: 19234142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Mutagenesis Can and Cannot Reveal About Allostery.
    Carlson GM; Fenton AW
    Biophys J; 2016 May; 110(9):1912-23. PubMed ID: 27166800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The WXXW motif in the TSR1 of ADAMTS13 is important for its secretion and proteolytic activity.
    Ling J; Su J; Ma Z; Ruan C
    Thromb Res; 2013 Jun; 131(6):529-34. PubMed ID: 23683325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.